SOURCE: Theravance, Inc.

September 13, 2005 17:00 ET

Theravance to Present at Global Pharmaceutical, Biotech & Medtech Conference

SOUTH SAN FRANCISCO, CA -- (MARKET WIRE) -- September 13, 2005 -- Theravance, Inc. (NASDAQ: THRX) announced today that Rick E. Winningham, Theravance's Chief Executive Officer, is scheduled to present at the Global Pharmaceutical, Biotech & Medtech Conference on Friday, September 16, 2005 at 2:10 p.m. BST. The conference will be held from September 13-16, 2005 at the Merrill Lynch Financial Centre in London, United Kingdom.

About Theravance

Theravance is a biopharmaceutical company with a pipeline of internally discovered product candidates. Of the six programs in development, two are in late stage -- telavancin and the Beyond Advair collaboration with GlaxoSmithKline. Theravance is focused on the discovery, development and commercialization of small molecule medicines across a number of therapeutic areas including respiratory disease, bacterial infections, overactive bladder and gastrointestinal disorders. By leveraging its proprietary insight of multivalency to drug discovery focused on validated targets, Theravance is pursuing a next generation drug discovery strategy designed to discover superior medicines in large markets. For more information, please visit the company's web site at www.theravance.com.

THERAVANCE®, the Theravance logo, and MEDICINES THAT MAKE A DIFFERENCE® are registered trademarks of Theravance, Inc. Theravance's September 16, 2005 presentation at the Global Pharmaceutical, Biotech & Medtech Conference will contain certain "forward-looking" statements as that term is defined in the Private Securities Litigation Reform Act of 1995 regarding, among other things, statements relating to goals, plans, objectives and future events. Examples of such statements include statements relating to the goals and expected results of clinical and preclinical studies, statements regarding the potential benefits and mechanisms of action of drug candidates and the enabling capabilities of Theravance's approach to drug discovery and its proprietary insights. These statements will be based on the current estimates and assumptions of the management of Theravance, Inc. as of the date of the presentation and are naturally subject to risks, uncertainties, changes in circumstances, assumptions and other factors that may cause the actual results of Theravance to be materially different from those reflected in its forward-looking statements. Important factors that could cause actual results to differ materially from those indicated by such forward-looking statements include, among others, risks related to delays or difficulties in commencing or completing clinical and preclinical studies, the potential that results of clinical or preclinical studies indicate product candidates are unsafe, ineffective, inferior or not superior, and delays or failure to achieve regulatory approvals. These and other risks are described in greater detail under the heading "Factors Affecting Results, Including Risks and Uncertainties" contained in Item 2, "Management's Discussion and Analysis of Financial Condition and Results of Operations" in Theravance's Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission (SEC) on August 12, 2005 and the risks discussed in our other filings with the SEC. Given these uncertainties, you should not place undue reliance on these forward-looking statements. Theravance assumes no obligation to update its forward-looking statements.

Contact Information

  • Contact Information:

    Investors
    Theravance, Inc.
    Michael Aguiar, SVP and CFO
    650-808-4100
    Email Contact

    Media
    Theravance, Inc.
    David Brinkley, SVP, Commercial Development
    650-808-3784
    Email Contact